UAE approves new drug for rare blood disorder that raises red blood cells and clot risk

Dubai: The United Arab Emirates has sanctioned a novel therapy for adults battling polycythemia vera, a scarce blood ailment where the body generates an excessive amount of red blood cells, amplifying the peril of perilous blood clots. The Emirates Drug Establishment (EDE) has endorsed MIMRYLO (rusfertide), designating the UAE as the second nation globally to authorize the medication, thereby broadening the treatment alternatives accessible to patients in the region.

Polycythemia vera is a rare, ongoing condition wherein the body yields a higher-than-usual quantity of red blood cells, rendering the blood denser and escalating the jeopardy of clots and other complications. MIMRYLO operates by aiding in the diminishment of red blood cell counts in individuals with the condition, thereby aiding in its control and management, as affirmed by the EDE on Wednesday.

Dr Fatima Al Kaabi, Director General of the EDE, highlighted that the approval underscores the Establishment's dedication to establishing a regulatory framework capable of keeping pace with advanced therapeutic innovations. She emphasized that the objective is to expedite access to such treatments via meticulous scientific evaluation that prioritizes patient safety in every decision.

Al Kaabi noted that this significance lies predominantly in rare diseases, where treatment options remain constrained for certain groups of patients. She added that the benefit of this approach rests in the efficacy of regulatory decisions and their alignment with health priorities, thereby enhancing the quality of care and fostering superior outcomes for patients.

Hernan Purcell, Regional General Manager for the Middle East and Turkey at Takeda Pharmaceuticals, hailed the approval as a pivotal milestone for those grappling with polycythemia vera. He underscored the company's commitment to developing medicines that address unmet medical needs and commended the EDE for championing pharmaceutical innovation, thus enabling patients to derive benefits from therapeutic advancements in a timely manner.